
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is supported by a compelling clinical thesis centered on vopimetostat, whose PRMT5-based combinations produced strong updated efficacy in 2L+ PDAC, including an 82% ORR, 100% DCR, and 88% 9-month PFS rate, with similarly encouraging activity in NSCLC. The company’s balance sheet also strengthens the outlook, as it ended 3Q26 with $977.5M in cash, cash equivalents, and marketable securities, which may provide an operational runway potentially into profitability despite a projected full-year 2026 net loss of $1.50 per share. Near-term catalysts in January 2027 and 1H27, including lung cancer, glioblastoma, and Phase 3 trial initiations, could further validate the pipeline and expand the addressable opportunity.
Bears say
Tango Therapeutics is exposed to substantial fundamental risk because its outlook depends on unproven clinical assets, including TNG-908 and the USP1i program, that may fail to demonstrate efficacy or may encounter safety issues severe enough to halt development. As a biotechnology company with a narrow pipeline concentrated in precision oncology, it faces meaningful regulatory and commercialization uncertainty, especially if current or future therapies compete more effectively against its candidates. The negative stance is reinforced by the possibility that the company cannot achieve sales estimates, leaving it reliant on programs that remain vulnerable to clinical, regulatory, and market setbacks.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Tango Therapeutics (TNGX) Forecast
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares